<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02740777</url>
  </required_header>
  <id_info>
    <org_study_id>311-HPV-1004</org_study_id>
    <nct_id>NCT02740777</nct_id>
  </id_info>
  <brief_title>Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females</brief_title>
  <official_title>Immunogenicity Study of a 2-dose Immunization Schedule of Recombinant Human Papillomavirus Virus-like Particle Vaccine (Type 16 and 18 L1 Proteins, Yeast) in Adolescent Females Aged 9 to 14 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zerun Biotechnology Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangxi Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Zerun Biotechnology Co.,Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the immune non-inferiority, as measured by antibody responses, of a 2-dose&#xD;
      immunization schedule (0, 6 months) of recombinant human papillomavirus virus-like particle&#xD;
      vaccine (type 16 and 18 L1 proteins, yeast) (hereinafter referred as HPV-2 vaccine) in&#xD;
      adolescent females aged 9 to 14 years in comparison to 3-dose immunization schedule (0, 2, 6&#xD;
      months) in young females aged 18 to 26 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study plans to enroll 600 adolescent females aged 9 to 14 years and 300 adult females&#xD;
      aged 18 to 26 years. The adolescents will be divided into two cohorts, 300 each, receiving&#xD;
      either a 2-dose (0, 6 months) immunization schedule or a 3-dose (0, 2, 6 months) immunization&#xD;
      schedule. The adult female group will receive a 3-dose (0, 2, 6 months) immunization&#xD;
      schedule.&#xD;
&#xD;
      Each subject shall be administrated with the studied vaccine according to either 2-dose or&#xD;
      3-dose schedule as above. Immediate reactions occurred during 30 minutes after each&#xD;
      inoculation, all the local and systematic reactions occurred from 0 to 7 days after each&#xD;
      inoculation will be recorded. All the adverse events (AEs) occurred from the first dose of&#xD;
      administration to 1 month after the final dose of administration, as well as all the serious&#xD;
      adverse events (SAEs) occurred from the first dose of administration to 6 months after the&#xD;
      final dose of administration will be collected. Blood samples will be collected at day 0&#xD;
      (prior to immunization) , month 6 (prior to the last injection) , month 7, month 12, month&#xD;
      24, and month 36. All the blood samples will be tested HPV 16- and HPV 18-specific antibody&#xD;
      titers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HPV-16 and HPV-18 antibody titers (GMT)</measure>
    <time_frame>one month after the final injection</time_frame>
    <description>Compare the HPV-16 and HPV-18 specific antibody titers (GMT) between the 2-dose immunization schedule (0, 6 months) in adolescent females aged 9 to 14 years and the 3-dose immunization schedule (0, 2, 6 months) in young females aged 18 to 26 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HPV-16 and HPV-18 antibody titers (GMT) and the seroconversion rate</measure>
    <time_frame>30 months after the final injection</time_frame>
    <description>Compare the immunogenicity between the 2-dose (0, 6 months) and the 3-dose (0, 2, 6 months) immunization schedules in adolescent females aged 9-14 years, on the basis of: 1) antibody titers (GMT) and the seroconversion rate at one month after the final injection, 2) antibody titer persistence and 3) antibody titers at a steady status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local and systemic adverse events (AEs)</measure>
    <time_frame>6 months after the final injection</time_frame>
    <description>Evaluate all local and systemic adverse events (AEs) occurred within 7 days after each inoculation, at one month and 6 month after the whole immunization</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Human Papillomavirus</condition>
  <condition>Cervical Intraepithelial Neoplasia</condition>
  <condition>Persistent Infection</condition>
  <arm_group>
    <arm_group_label>2-dose adolescent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 adolescent girl will receive a two-dose schedule (0 day, 6 months) immunization of HPV-16/18 vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3-dose adolescent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 adolescent girl will receive a three-dose schedule (0 day, 2 months, 6 months) immunization of HPV-16/18 vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3-dose adult</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 adult women will receive a three-dose schedule (0 day, 2 months, 6 months) immunization of HPV-16/18 vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HPV-16/18 vaccine</intervention_name>
    <description>HPV 16 L1 virus like particles (VLP) 40μg; HPV 18 L1 VLP 20μg; Aluminium phosphate 225μg; NaCl 0.32M; Histidine buffer 10mM; Tween-80 0.01%.</description>
    <arm_group_label>2-dose adolescent</arm_group_label>
    <arm_group_label>3-dose adolescent</arm_group_label>
    <arm_group_label>3-dose adult</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Adult group:&#xD;
&#xD;
          -  18-26 healthy female&#xD;
&#xD;
          -  enable to provide an legal identification&#xD;
&#xD;
          -  have the ability to understand and sign the Informed Consent Form&#xD;
&#xD;
          -  aren't pregnant and do not have pregnancy plan within the 7 months after the first&#xD;
             injection&#xD;
&#xD;
          -  used effective contraceptive method from the last menstruation, and agreed to avoid&#xD;
             sexual activity without effective contraceptive method within the 15 days after&#xD;
             injection&#xD;
&#xD;
        Adolescent group:&#xD;
&#xD;
          -  9-14 healthy female&#xD;
&#xD;
          -  enable to provide an legal identification&#xD;
&#xD;
          -  guardians have the ability to understand the Informed Consent Form, and both&#xD;
             participant and guardian agreed to sign the Form (in case of unable to sign, the&#xD;
             participant can use fingerprint as signature)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of HPV infection&#xD;
&#xD;
          -  Previous administration of any HPV vaccine&#xD;
&#xD;
          -  History of severe allergic reaction requiring medical intervention (such as oral and&#xD;
             throat swelling, difficulty breathing, hypotension or shock)&#xD;
&#xD;
          -  History of allergic to vaccine, or to any ingredient of vaccine.&#xD;
&#xD;
          -  History of epilepsy, seizures or convulsions, or family history of mental illness&#xD;
&#xD;
          -  Subjects are immunocompromised or have been diagnosed as suffering from congenital or&#xD;
             acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus&#xD;
             erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis inflammation&#xD;
             (JRA), inflammatory bowel disease or other autoimmune diseases, administration of&#xD;
             immunosuppressants with six months prior to the first vaccine dose.&#xD;
&#xD;
          -  History of asthma, thyroidectomy, angioneurotic edema, diabetes or malignant&#xD;
&#xD;
          -  Asplenia, functional asplenia, or any circumstances result of asplenia or splenectomy&#xD;
&#xD;
          -  Medical diagnosis of coagulation abnormalities (eg, clotting factor deficiency,&#xD;
             coagulation disorders, platelet anomaly) or obvious bruising or coagulation disorder&#xD;
&#xD;
          -  Acute disease or chronic disease acute exacerbation 7 days prior to vaccination&#xD;
&#xD;
          -  Administration of immunoglobulins and/or any blood products within 3 months, or&#xD;
             administration of any live attenuated vaccine within 28 days, or administration of any&#xD;
             subunit or inactivated vaccines within 14 days.&#xD;
&#xD;
          -  Fever or axillary temperature&gt; 37.0 °C before vaccination&#xD;
&#xD;
          -  During menstrual period, breastfeeding, pregnancy(pregnancy test positive), or planned&#xD;
             pregnant within 7 month&#xD;
&#xD;
          -  History of hypertension, physical examination systolic blood pressure&gt; 150mmHg and/or&#xD;
             diastolic blood pressure&gt; 100mmHg&#xD;
&#xD;
          -  Abnormal laboratory tests parameters&#xD;
&#xD;
          -  Any clinical significant disease or findings during study screening that, in the&#xD;
             opinion of the Investigator may interfere with the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhaojun Mo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangxi Center for Disease Prevention and Control(GXCDC)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhaojun Mo</last_name>
    <phone>+86 771-2518780</phone>
    <email>mozhj@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hezhou Center for Disease Prevention and Control</name>
      <address>
        <city>Hezhou</city>
        <state>Guangxi</state>
        <zip>542899</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Youshou Li</last_name>
      <phone>086-774-5139230</phone>
      <email>hzsswzp@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Center for Disease Prevention and Control</name>
      <address>
        <city>Zhongshan</city>
        <state>Guangxi</state>
        <zip>542699</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guide Nong</last_name>
      <phone>086-13321645288</phone>
      <email>zscdcxmb8989268@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>April 5, 2016</study_first_submitted>
  <study_first_submitted_qc>April 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2016</study_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

